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Background: Although pneumoperitoneum has been suspected as a possible cause of 
transient elevation of liver function tests (LFTs) after laparoscopic surgery, liver damage by 
direct retraction could also influence postoperative LFTs. The aim of this study was to 
clarify whether laparoscopic gastrectomy (LG) using a Nathanson retractor was associated 
with the postoperative elevation of LFTs compared with open gastrectomy (OG). 
Methods: A retrospective cohort study of 199 LG and 120 OG patients was conducted. 
Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total 
bilirubin were measured before operation and at postoperative days 1, 3, and 7. The 
abnormal elevation of LFTs was defined as grade 2 or greater elevation in any parameter. 
To assess the possible effect of pneumoperitoneum, patients who underwent laparoscopic 
(n=324) and open (n=56) colectomy for colorectal cancer were also compared. 
Results: In both LG and OG groups, LFTs were significantly elevated postoperatively 
compared with baseline values. Mean ALT and total bilirubin levels on days 1, 3, and 7 
were significantly higher in the LG than OG group. Abnormal elevation of LFTs was more 
frequent in the LG than OG group (50 vs. 12%). In the multivariate analysis, LG was 
significantly associated with postoperative liver dysfunction (odds ratio=7.99; 95% 
confidence interval 3.69 to 18.85). No significant difference in the LFTs elevation was 
observed between laparoscopic and open colectomy (6% and 9%, respectively). 
Conclusions: LG resulted in frequent elevation of LFTs. Care should be taken to minimize 





ALHA: Aberrant left hepatic artery 
ALT: Alanine aminotransferase 
AST: Aspartate aminotransferase 
ASA: American Society of Anesthesiology Classification 
CI: Confidence interval 
LFTs: Liver function tests 
LG: Laparoscopic gastrectomy 
LC: Laparoscopic colectomy 
NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events 
OC: Open colectomy 
OG: Open gastrectomy 




To pursue minimal invasive surgery for gastric cancer, laparoscopic gastrectomy (LG) 
was developed and has been increasingly applied in recent years. Several case series 
studies reported the safety and clinical benefits of LG, including early postoperative 
recovery and better cosmetic results [1-3]. A recent phase II feasibility study of LG in 
Japanese patients has reported low frequency (9.1%) of surgical overall complications, 
confirming its safety when performed by experienced surgeons [4]. 
Although overall surgical morbidity does not seem to increase with LG, some studies 
have shown transient elevation of liver function tests (LFTs) in a substantial proportion of 
patients after LG [5-7]. Similar transient alterations in LFTs have been reported in other 
types of laparoscopic surgery, such as cholecystectomy, colectomy, gastric bypass, and 
Nissen fundoplication [5, 8-13]. Some studies suggest that the increase in intraabdominal 
pressure by pneumoperitoneum impairs hepatic venous outlet, and causes transient liver 
damage [5-7]. 
Other possible causes of postoperative liver dysfunction in laparoscopic surgery include 
patient position, anesthetic agents, division of aberrant left hepatic artery (ALHA), and 
direct liver manipulation [5, 6, 10-12, 14-16]. Among these factors, liver manipulation 
should have greater impact on LG, because it is critical to retract the overhanging hepatic 
lateral lobe for lymph node dissection. We have introduced a Nathanson liver retractor in 
LG to maintain a good operative field. Although some studies of antireflux or bariatric 
surgery have suggested that this method could cause postoperative liver dysfunction [12], 
the effect of routine use of the Nathanson liver retractor in LG on postoperative LFTs has 
not been investigated. 
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The aim of this study was to clarify whether LG using a Nathanson retractor was 
associated with the postoperative elevation of LFTs compared with open gastrectomy (OG) 
under appropriate adjustment for imbalance of the patient’s clinicopathological 
characteristics and potential confounders. In addition, to evaluate the possible effect of 
pneumoperitoneum on transient liver dysfunction, the incidence and the extent of liver 
enzyme elevations between laparoscopic colectomy (LC) and open colectomy (OC) were 
compared. 
 
Materials and Methods 
Patients 
This study was approved by the ethics committee of Kyoto University. All consecutive 
373 patients with histologically proven primary gastric cancer who underwent total or 
distal gastrectomy in our institution between July 2005 and March 2010 were reviewed. To 
regulate imbalances in patient’s preoperative liver function, the following patients were 
excluded: (1) those with liver metastasis or primary liver tumors, (2) those with chronic 
hepatic disease, such as HBs antigen positive, Hepatitis C virus positive, autoimmune liver 
disease, and alcoholic hepatitis, and (3) those with grade 2 or greater abnormal increase of 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), and/or total bilirubin 
on preoperative laboratory tests as classified according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. As a result, 
319 patients were included for the analysis. Among them, 199 patients underwent LG (LG 
group) and 120 patients underwent OG (OG group). To examine the sole effect of 
pneumoperitoneum on transient liver dysfunction, all 560 consecutive patients with 
histologically proven primary colorectal cancer who underwent colectomy in our institution 
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during the same period were also reviewed. After exclusion of patients according to the 
same criteria, the laparoscopic colectomy (LC) and the open colectomy (OC) group 
comprised 324 and 56 patients, respectively. Patients who required conversion from 




The procedure for LG was previously described in detail [17, 18]. Briefly, the patient was 
placed in a modified lithotomy position. After the first port was inserted through the 
umbilicus and CO2 pneumoperitoneum at 8 mmHg was established, four operating ports 
were placed. A Nathanson liver retractor (Cook Japan, Tokyo, Japan) was inserted and 
fixed with a retractor holder with an appropriate fashion. During the procedure, the patient 
was placed in the reverse Trendelenburg’s position. Lymph node dissection was carried out 
with the use of ultrasonically activated coagulating shears (SonoSurg®; Olympus, Tokyo, 
Japan), and the stomach was resected using endoscopic linear staplers. Intracorporeal 
reconstruction was then carried out either with the Billroth-I or Roux-en-Y method [14], 
[19]. 
OG was performed through an upper transverse laparotomy incision. Lymph node 
dissection was performed using a monopolar and bipolar electric cautery. A blade type liver 
retractor for open surgery was routinely used with a retractor holder, when performing 
dissection of suprapyloric or subcardial lymph nodes. Reconstruction was performed with a 
Roux-en-Y method in both distal and total gastrectomy. 
Radical lymphadenectomy which was defined as D2 or ‘‘modified D2’’ lymph node 
dissection was performed in both groups. D2 was defined according to the general rules of 
7 
 
the Japanese Association of Gastric Cancer (13th edition) [20], whereas lymph node 
stations #12a and/or #14v were not dissected in ‘‘modified D2’’. In all cases, prophylactic 
antibiotics were administered prior to and every three hours during the operation. 
 
Preoperative patient assessment 
All patients had detailed preoperative risk assessments based on clinical presentation, 
chest radiography, electrocardiography, and pulmonary function tests. Preoperative tumor 
staging was based on physical examination, radiologic examination (computed tomography 
and/or magnetic resonance imaging), upper gastrointestinal series, ultrasonography, and 
endoscopy. Before April 2009, LG was only applied to patients with a tumor depth limited 
to T3 (SS), and without lymph node metastases. After that period, indication of LG was 
extended to patients with more advanced diseases. 
 
Data extraction and blood samples 
Data of baseline clinical characteristics, operative parameters, postoperative 
complications, and pathological reports were extracted from the prospectively maintained 
database of patients who underwent gastrectomy in our department. Laboratory data were 
collected from medical charts. Blood samples were obtained before operation and on 
postoperative days 1, 3, and 7, to measure serum AST, ALT, and total bilirubin levels. Total 
bilirubin, and AST and ALT activities were measured with an automatic analyzer (TBA-





The main study outcome was the incidence of “abnormal elevation of LFTs”. Parameters 
of liver function (AST, ALT, and total bilirubin) at each time point were classified according 
to the NCI-CTCAE grading system (version 4.0). “Abnormal elevation” was defined as a 
grade 2 or greater increase in LFTs at any time point, compared to the baseline. In the 
CTCAE, a grade 2 increase of AST and ALT was defined as >3.0  5.0 × upper limit of 
normal (ULN), and a grade 2 increase of total bilirubin was defined as >1.5  3.0 × ULN. In 
our institution, the ULNs of AST and total bilirubin were 33 IU/L and 1.3 mg/dL, 
respectively. The ULN of ALT was 42 IU/L for male, and 27 IU/L for female. 
Postoperative adverse events, such as pneumonia, pleural effusion, atelectasis, cardiac 
events (myocardial infarction, heart failure, arrhythmia), anastomotic leakage, anastomotic 
stenosis, ileus, diarrhea, and wound infection were classified according to the NCI-CTCAE. 
Postoperative complications were defined as grade 2 or greater adverse events that 
occurred within 30 days of the operation. The pathological classification of the primary 
tumor, the degree of lymph node involvement, and the presence of organ metastasis were 
defined according to the TNM classification (version 7), and R classification was used to 
describe the extent of residual disease after gastrectomy (R0: no residual tumor, R1: 
microscopic residual tumor, R2: macroscopic residual tumor) [21]. Thirty-day death was 
defined as death within 30 days of the operation. 
 
Statistical analysis 
Continuous variables are presented as means (±SD), and were compared using Student’s 
t test. Categorical data were compared with the 2 test. Logistic regression models were 
used to compare the occurrence of abnormal elevation of LFTs between the LG and OG 
groups. Univariate and multivariate analyses were performed for independent variables. 
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Variables with a p value <0.20 in the univariate analysis were included in the multivariate 
analysis. In the multivariate analysis, a p value <0.05 was considered statistically 
significant. All statistical analyses were performed with JMP version 8.0.2 software (SAS 




Patient characteristics and surgical outcomes 
The clinical and pathologic characteristics of eligible 319 gastric cancer patients are 
shown in Table 1. There was no significant difference in age, gender, body mass index, 
alcohol use, and medical history. More patients in the OG group received neoadjuvant 
chemotherapy (25% vs 7%) and underwent total gastrectomy (50% vs 32%) than in the LG 
group. The mean preoperative serum albumin in the LG group was higher than that in the 
OG group. Reflecting the difference of operative indication, the LG group included fewer 
patients with an advanced stage, lymph node metastasis, or T3/4 tumors compared with the 
OG group. 
Surgical outcomes are shown in Table 2. LG was performed with significantly less blood 
loss compared to OG (80 vs 472 g, p < 0.001), while the operation time for LG was longer 
than that for OG (301 vs 271 min, p = 0.049). In addition, hospital stay was significantly 
shorter in the LG group. There was a higher proportion of LG patients with an earlier 
stage; R0 was achieved in 96% of these patients, while 25% of the OG patients resulted in 
R1/2 resection. Overall complications were significantly less in the LG group (18 patients; 
9%) than in the OG group (22 patients; 18%) (p = 0.015). Liver infarction was diagnosed by 
computed tomography in one LG patient (Figure 1)—spiking fever in this patient subsided 
with antibiotics treatment within a week. One patient in each group underwent reoperation 
due to anastomotic leakage, and one patient who underwent laparoscopic total gastrectomy 
had a reoperation due to ischemic perforation of the ileum. The patient was a 77-year-old 
woman with diabetes mellitus and hypertension, and pathological examination revealed the 
segmental ischemia of ileum due to thromboembolic occlusion of the mesenteric artery. 
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Because we did not manipulate the ileum during LG, the complication was not directly 
related to the intra-operative procedure. 
Details of the clinical and pathological features of 380 colorectal cancer patients are 
shown in Table 3. There were no significant differences in age, gender, body mass index, 
tumor site, or operation time between the LC and OC groups. Mean blood loss in the LC 
group was significantly less than that in the OC group (33 vs 430 g, p < 0.001). In addition, 
the LC group included more patients with an earlier pathological tumor stage. 
 
Comparison of abnormal elevation of LFTs between LG and OG 
The laboratory data of LFTs are listed in Table 4 and shown in Figure 2. In both LG and 
OG groups, AST and ALT levels were significantly elevated after the operation compared 
with the baseline values and reached peaks on the first postoperative day. AST levels 
decreased more rapidly than ALT levels in both groups and returned to baseline at day 7. 
No increase in either the AST or ALT level was observed in the LC or OC group. Total 
bilirubin levels were significantly elevated compared to the baseline values in all groups, 
and gradually decreased to baseline at day 7. 
In comparison between the LG and OG groups, mean AST levels on postoperative days 1 
and 3, and mean ALT and total bilirubin levels on days 1, 3, and 7, were significantly 
higher in the LG group (p < 0.001), indicating the delayed recovery of ALT and total 
bilirubin levels in these patients. 
“Abnormal elevation of LFTs”, which was defined as a grade 2 or greater elevation in 
either parameter, was observed in 99 out of the 199 LG patients (50%). On the other hand, 
only 14 out of the 120 OG patients (12%) showed an increased level of LFTs. There was no 
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significant difference in the incidence of altered LFTs between LC and OC groups (6% and 
9%, respectively). 
 
Univariate and multivariate analysis for the abnormal elevation of LFTs 
Univariate and multivariate logistic regression analyses regarding the incidence of 
abnormal elevation of LFTs were performed in all 319 patients who underwent gastrectomy 
(Table 5). In the univariate analysis, LG, serum albumin, cholecystectomy, and operation 
time were significant risk factors related to abnormal LFTs. In the multivariate model 
including variables with a p value <0.20 in the univariate analysis, LG was the only 
independent risk factor for abnormal elevation of LFTs (adjusted odds ratio = 7.99; 95% 
confidence interval 3.69 to 18.85; p < 0.001). Age, gender, body mass index, preoperative 
serum albumin, cholecystectomy, depth of tumor invasion, and lymph node metastasis were 
not associated with abnormal LFTs. 
 
Postoperative course of patients with elevated LFTs 
Postoperative course of patients with abnormally elevated LFTs after LG (n=99) was 
compared with that of LG patients without elevated LFTs (n=100). There was no significant 
difference in postoperative complications (10% vs 8%, p = 0.605). Mean postoperative 
hospital stay was also similar between the two groups (16 vs 14 days, p = 0.154). 
 
Discussion 
Our study showed that a significantly higher incidence of abnormal elevation of LFTs in 
the LG group than OG group. Notably, nearly half of the LG patients experienced more 
than three times elevation of liver enzymes postoperatively. Because this is an 
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observational study, careful analysis and interpretation of results is necessary. First, in 
consideration of confounding factors, we excluded cases of liver tumor or liver disease to 
reduce the factors affecting postoperative liver function. Second, selection bias between the 
two groups should be considered. Because LG was applied only for patients with a tumor 
depth of T3 (SS) in the earlier period of this study, tumor stage or metastatic status were 
not matched between the LG and OG groups. To control for such imbalance, a logistic 
regression model was adopted. Even after adjustment for these potential confounders, LG 
remained the only factor responsible for abnormal elevation of LFTs. 
In previous studies, factors such as anesthetic agents, patient position, direct liver 
manipulation, division of an aberrant left hepatic artery (ALHA), and pneumoperitoneum 
have been reported as possible causes for transient liver enzyme elevation after 
laparoscopic surgery [5, 6, 10-12, 15, 16]. Among these factors, anesthetic agents were the 
same in both groups in our study. Pneumoperitoneum has been argued to be the main cause 
of postoperative hepatic dysfunction in several studies regarding laparoscopic surgery [5, 8-
13]. A decreased blood flow in the liver due to the pressure of pneumoperitoneum has been 
suggested as the possible mechanism. However, a study using transesophageal 
echocardiography has demonstrated an opposite effect of pneumoperitoneum—an elevated 
hepatic flow during laparoscopic procedures [22]. Moreover, in a large case series study of 
more than 1000 laparoscopic cholecystectomies, postoperative LFT was elevated in only 
3.9% of patients [8]. In our study, to exclude the effect of liver manipulation and to 
investigate the sole effect of pneumoperitoneum on LFTs, patients who underwent LC were 
examined. Abnormal elevation of LFTs was observed in only 6% of the LC patients, which is 
similar to 9% of the OC patients. A head-up position may cause enhanced reduction of 
hepatic blood flow under pneumoperitoneum[14]. However, abnormal elevation of LFTs was 
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not increased in patients who underwent LC in a head-up position compared to patients in 
a head-down position in our study (4.4% vs 5.5%). These data together strongly suggest that 
pneumoperitoneum and patient position are not responsible for the postoperative abnormal 
LFTs in patients who underwent laparoscopic surgery.  
Transient changes in LFTs are also observed in patients who undergo OG. Previous 
studies have indicated that division of the ALHA during lymphadenectomy could affect 
postoperative LFTs [16, 23]. Although there is controversy whether the ALHA should be 
preserved during lymphadenectomy, postoperative liver dysfunctions were reported to be 
transient and resumed within a week. Thus, to ensure en bloc dissection of lymph nodes, we 
routinely divide the left gastric artery at its root even when the ALHA is recognized during 
the procedure. Because this policy was equally applied to the LG and OG group, the effect 
of the division of the ALHA should be the same between the two groups. Nevertheless, only 
in the LG group, did half of the patients experience abnormal elevation of LFTs 
postoperatively. Although a frequency of the ALHA ranged from 12 to 20% in the literature 
[3, 24, 25], the ligation of the ALHA alone could not explain the high frequency of liver 
dysfunction in the LG group. 
As Jeong et al. suspected in a recent study, direct liver manipulation is the another 
possible cause [5-7]. In gastric cancer surgery, liver retraction is essential for performing 
lymphadenectomy along the lesser curvature, the hepatoduodenal ligament, and the 
cardiac area. For LG, we introduced a Nathanson liver retractor, which has been applied in 
laparoscopic upper gastrointestinal surgery in western countries for years. Although this 
retractor provides a good operative field, elevation of liver enzymes has been reported in 
some studies of laparoscopic fundoplication or gastric bypass [12, 15]. Among three previous 
studies examining liver functions after LG, only Shinohara et al. used a Nathanson 
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retractor; one study used a snake retractor (Diamond-Flex®; Snowden Pencer, USA) and 
the other did not mention the liver retraction method. In Shinohara’s and our studies using 
a Nathanson retractor, peak ALT values were 213 and 153, which are much higher than 
those reported in the other two studies (56 and 89, respectively). These observations 
suggest that heavier retraction by a Nathanson retractor might cause more severe damage 
to the liver than the other method. In addition, two studies using a Nathanson retractor 
required a longer operation time than in the others (333 and 301 vs 270 and 230 min). 
Because operation time was also significantly longer in patients with elevated LFTs in our 
study, this factor could also adversely affect the postoperative LFTs. In fact in the LG group, 
abnormal elevation of LFTs was more frequently observed in patients who underwent total 
gastrectomy which required a longer operation time and heavier retraction compared to 
patients who underwent distal gastrectomy in our study (60% vs 45%). 
We experienced a focal liver infarction in the lateral segment in one LG patient. Both 
injury to the hepatic artery and liver retraction are suspected as causes of liver infarction 
following gastrectomy [26]. In this patient, ALHA was recognized and divided during 
surgery, while the proper hepatic artery was safely preserved. Because the infarction was 
focal and consistent with the area where a Nathanson retractor was placed, ischemia could 
also be a result of the intense retraction. 
In conclusion, the current study demonstrated that LG results in frequent elevation of 
LFTs compared with OG. Liver retraction by a Nathanson retractor could be a major cause. 
Although elevated liver enzymes subsided spontaneously and usually do not affect patient 
recovery, rare complications such as liver infarction could happen. Therefore, care should 
be taken to minimize the intraoperative liver damage when performing LG, by decreasing 
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Liver infarction following laparoscopic gastrectomy. Contrast-enhanced computed 
tomography revealed a wedge-shaped low-attenuation area in the lateral segment on the 
fourth operative day. 
 
Fig. 2 
Time-course changes in liver function tests following gastrectomy. (A) Aspartate 
aminotransferase (AST). (B) Alanine aminotransferase (ALT). (C) Total bilirubin. *p<0.01 





Table 1 Clinical and pathological characteristics of gastric cancer patients 
 LG OG  
Variable (n=199) (n=120) p value 
Age (years)* 64.0±11.9 66.5±11.3 0.073 
Gender (male:female) 125 : 74 86 : 34 0.106 
Body mass index* 22.0±3.3 21.5±3.6 0.203 
ASA-PS   0.009 
     I 149 (75%) 73 (61%)  
     II 50 (25%) 47 (39%)  
Alcohol use 106 (53%) 65 (38%) 0.875 
Cardiovascular disease 21 (11%) 15 (13%) 0.594 
Diabetes mellitus 34 (17%) 14 (12%) 0.190 
Serum albumin (g/dL)* 4.1±0.4 3.8±0.5 <0.001 
Neoadjuvant chemotherapy 14 (7%) 30 (25%) <0.001 
Extent of resection   0.001 
     Total 63 (32%) 60 (50%)  
     Distal 136 (68%) 60 (50%)  
Cholecystectomy 10 (5%) 49 (41%) <0.001 
Tumor site   0.128 
     Upper 48 (24%) 39 (33%)  
     Middle 78 (39%) 35 (29%)  
     Lower 73 (37%) 46 (38%)  
Tumor stage   <0.001 
     I 147 (73%) 31 (26%)  
     II 28 (14%) 22 (18%)  
     III 17 (9%) 31 (26%)  
     IV 7 (4%) 36 (30%)  
Depth of tumor invasion   <0.001 
     pT1, 2 160 (80%) 41 (34%)  
     pT3, 4 39 (20%) 79 (66%)  
Lymph node metastasis   <0.001 
     pN0 148 (74%) 41 (34%)  
     pN1-3 51 (26%) 79 (66%)   
Extent of node dissection   <0.001 
     D1, modified D2 108 (54%) 25 (21%)  
     D2, D3 91 (46%) 95 (79%)  
*Values are means±SD. LG: laparoscopic gastrectomy; OG: open gastrectomy; ASA: 
American Society of Anesthesiology Classification. 
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 Table 2 Surgical outcomes of gastric cancer patients 
 LG OG  
 (n=199) (n=120) p value 
Operative blood loss (g)* 80 (5-3600) 472 (10-3400) <0.001 
Operation time (min)* 301 (179-560) 271 (60-1480) 0.049 
Residual tumor   <0.001 
     R0 192 (96%) 90 (75%)  
     R1-R2 7 (4%) 30 (25%)  
Reoperation 2 (1%) 1 (1%) 0.878 
Postoperative hospital stay (days)* 12 (7-85) 15 (8-71) <0.001 
Overall surgical complications 18 (9%) 22 (18%) 0.015 
     Pneumonia 6 4  
     Pleural effusion 2 4  
     Atelectasis 4 3  
     Arrhythmia 2 0  
     Enteritis 0 1  
     Diarrhea 0 1  
     Ileus 2 2  
     Anastomotic leakage 5 4  
     Anastomotic stenosis 1 2  
     Liver infarction 1 0  
     Wound infection 2 7  
Death within 30 days 0 0  
*Values are means±SD. LG: laparoscopic gastrectomy; OG: open gastrectomy; R0: no 
residual tumor; R1: microscopic residual tumor; R2: macroscopic residual tumor. 
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Table 3 Clinical characteristics and surgical outcomes of colorectal cancer patients 
 LC OC  
Variable (n=324) (n=56) p value 
Age (years)* 67.4±11.0 68.4±13.9 0.547 
Gender (male:female) 193 : 131 33 : 23 0.928 
Body mass index* 22.1±3.3 21.5±3.3 0.191 
Tumor site   0.613 
     Cecum / Ascending 56 (18%) 14 (24%)  
     Transverse 27 (8%) 6 (11%)  
     Descending 21 (6%) 5 (9%)  
     Sigmoid 89 (27%) 10 (18%)  
     Recto-sigmoid 35 (11%) 7 (13%)  
     Rectum 96 (30%) 14 (25%)  
Tumor stage   <0.001 
     0 23 (7%) 5 (9%)  
     I 80 (25%) 4 (7%)  
     II 109 (34%) 26 (46%)  
     III 100 (30%) 11 (20%)  
     IV 12 (4%) 10 (18%)  
Operative blood loss (g)† 33 (0-900) 430 (15-7030) <0.001 
Operation time (min)† 244 (98-637) 234 (105-626) 0.074 






Table 4 Laboratory data and incidence of abnormal elevation of LFTs 
 LG OG  LC OC  
 (n=199) (n=120) p1 (n=324) (n=56) p2 
AST (IU/dL)*       
     Baseline 23.6±11.1 26.8±14.2 0.024 21.3±8.5 22.1±8.5 0.557 
     Day 1 151.7±231.3 72.1±109.5 <0.001 23.0±14.1 23.6±12.7 0.788 
     Day 3 50.4±63.2 35.7±30.4 0.017 25.5±18.4 23.6±10.3 0.462 
     Day 7 26.2±13.6 24.5±14.1 0.287 23.7±15.7 24.2±23.3 0.842 
ALT (IU/dL)*       
     Baseline 21.4±13.3 20.9±12.7 0.751 19.3±12.2 19.5±12.4 0.904 
     Day 1 153.8±244.8 50.8±87.4 <0.001 17.5±11.9 22.8±53.8 0.111 
     Day 3 97.9±145.3 36.5±51.7 <0.001 19.4±12.2 16.4±7.9 0.079 
     Day 7 44.1±40.0 26.1±17.0 <0.001 26.0±24.5 21.7±18.7 0.214 
Bilirubin (mg/dL)*       
     Baseline 0.8±0.3 0.6±0.3 <0.001 0.7±0.3 0.7±0.3 0.353 
     Day 1 1.1±0.5 0.9±0.4 <0.001 0.9±0.5 0.9±0.6 0.575 
     Day 3 1.1±0.8 0.8±0.3 <0.001 0.8±0.4 0.7±0.5 0.126 
     Day 7 0.9±0.9 0.6±0.3 <0.001 0.6±0.2 0.6±0.6 0.73 
Abnormal elevation of LFTs 
(Grade 2) 
      
     AST 76 (38%) 11 (9%) <0.001 7 (2%) 1 (2%) 0.857 
     ALT 80 (40%) 9 (8%) <0.001 5 (2%) 1 (2%) 0.893 
     Bilirubin 25 (13%) 3 (3%) 0.002 11 (3%) 3 (5%) 0.472 
     Total 99 (50%) 14 (12%) <0.001 19 (6%) 5 (9%) 0.384 
*Values are means±SD. LG: laparoscopic gastrectomy; OG: open gastrectomy; LC: laparoscopic colectomy; OC: open colectomy; 




Table 5 Results of univariate and multivariate analyses for postoperative abnormal elevation of LFTs in 319 gastric cancer 
patients. 
  Univariate analysis  Multivariate analysis 
Variable Category OR (95%CI) p value  OR (95%CI) p value 
Procedure LG vs OG 7.50 (4.14-14.49) <0.001  7.99 (3.69-18.85) <0.001 
Age per years 0.99 (0.97-1.01) 0.186  0.99 (0.97-1.02) 0.449 
Gender Male vs Female 0.63 (0.39-1.01) 0.057  0.65 (0.37-1.14) 0.133 
Body mass index  per kg/m2 1.07 (0.99-1.14) 0.050  1.08 (1.00-1.18) 0.052 
ASA-PS 2 vs 1 0.75 (0.45-1.24) 0.264    
Serum albumin per g/dL 2.07 (1.21-3.67) 0.007  1.51 (0.76-3.08) 0.242 
Alcohol use (+) vs (-) 1.28 (0.81-2.03) 0.298    
Cardiovascular disease (+) vs (-) 0.67 (0.30-1.41) 0.300    
Diabetes mellitus  (+) vs (-) 1.23 (0.65-2.30) 0.516    
Neoadjuvant 
chemotherapy 
(+) vs (-) 0.93 (0.47-1.80) 0.842    
Extent of resection Total vs Distal 1.03 (0.64-1.64) 0.918    
Cholecystectomy  (+) vs (-) 0.23 (0.10-0.48) <0.001  0.48 (0.18-1.20) 0.128 
T T3, 4 vs T0-2 0.71 (0.43-1.14) 0.158  2.14 (0.99-4.76) 0.056 
N N1-3 vs N0 0.71 (0.44-1.13) 0.148  1.23 (0.61-2.49) 0.570 
Operation time per minute 1.00 (1.00-1.01) 0.038  1.00 (0.99-1.00) 0.192 
LFTs: liver function tests; OR: odds ratio; CI: confidence interval; LG: laparoscopic gastrectomy; OG: open gastrectomy, ASA: 
American Society of Anesthesiology Classification; B-I: Billroth-I; R-Y: Roux-en-Y. 
